Shenzhen Zhongge Biotechnology patents new PTPN2 inhibitors
Feb. 6, 2025
Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer.